Skip to content
Inciteful Med

Standard of Care and Treatment Options

Last updated:

Treatment for Hereditary Elliptocytosis depends on severity. Mild cases typically require only observation and folic acid supplements. Severe HE or HPP may require phototherapy for newborns, regular red blood cell transfusions, or surgical removal of the spleen to manage anemia.

Key Takeaways

  • • Mild Hereditary Elliptocytosis is usually managed with regular monitoring and daily folic acid supplements to support red blood cell production.
  • • Severe cases, including Hereditary Pyropoikilocytosis (HPP), may require phototherapy for newborns or regular blood transfusions to treat anemia.
  • • A splenectomy can significantly improve severe anemia by preventing the premature destruction of elliptical red blood cells.
  • • Because HE patients process high levels of bilirubin, they are at high risk for gallstones and may require surgical removal of the gallbladder.
  • • New oral medications like Mitapivat are currently being studied in clinical trials to help improve red blood cell membrane stability.

Because Hereditary Elliptocytosis (HE) affects everyone differently, treatment is never “one size fits all.” For most, management is simple and involves monitoring, while for those with the severe form (Hereditary Pyropoikilocytosis or HPP), more intensive care is required from the very beginning [1][2].

For Mild and Asymptomatic HE

The majority of people with HE fall into this category. If your body is effectively replacing the red blood cells it loses, you may not need any active treatment [3][1].

  • Observation: Regular check-ups with a hematologist to monitor blood counts and check for an enlarged spleen or gallstones [3].
  • Folic Acid: Your doctor may recommend a daily supplement of folic acid. Because your body is working harder and faster to create new red blood cells to replace the elliptical ones, it needs more of this B-vitamin to keep up with production.

For Severe HE and HPP

In more severe cases, particularly in infants with HPP, the focus is on supporting the body and preventing complications from severe anemia [2][4].

  • Phototherapy: Newborns with severe HE or HPP often develop high levels of bilirubin (jaundice). They are treated with “bili-lights” (phototherapy) to help their bodies break down this pigment [4].
  • Transfusions: If anemia is severe enough to cause extreme fatigue, poor growth, or heart strain, red blood cell transfusions may be necessary [5][6]. Some children require regular transfusions for several years [5].

Surgical Interventions

For patients with severe chronic hemolysis or symptomatic complications, surgery may be recommended [7][8].

  • Splenectomy: The most significant medical intervention for severe HE or HPP is a splenectomy (surgical removal of the spleen) [7][9]. The spleen is the organ that identifies and destroys the abnormal elliptical cells. By removing it, the body allows these cells to circulate for much longer [10][9]. This can significantly improve anemia and eliminate the need for regular transfusions [8][11]. However, it does not “cure” the genetic defect; the cells remain elliptical [7]. Because the spleen is part of the immune system, removing it requires lifelong precautions, including specific vaccinations and sometimes daily antibiotics to prevent serious infections [12][13].
  • Cholecystectomy: Because patients with HE process high levels of bilirubin, they are at a high risk for developing gallstones [9][3]. If these gallstones become symptomatic (causing severe pain or blockages), a cholecystectomy (surgical removal of the gallbladder) is the standard treatment [8]. This is often performed at the same time as a splenectomy if both are needed [8].

Emerging Research: Mitapivat

Researchers are currently investigating new medications, such as Mitapivat, an oral medication (a pill), for various red blood cell disorders [14]. Early studies suggest this pill may help improve the energy and stability of red blood cell membranes in patients with structural defects [15][16]. While not yet a standard treatment for HE, it represents a promising area of ongoing clinical trials [14].

Frequently Asked Questions

Do I need treatment for mild Hereditary Elliptocytosis?
Most people with mild HE do not need active treatment. If your body is effectively replacing the red blood cells it loses, your doctor may only recommend regular observation and a daily folic acid supplement to support cell production.
Why might a newborn with HE or HPP need phototherapy?
Newborns with severe HE or Hereditary Pyropoikilocytosis (HPP) often develop high levels of bilirubin, leading to jaundice. Phototherapy, also known as bili-lights, helps their bodies safely break down this excess pigment.
How does a splenectomy help treat Hereditary Elliptocytosis?
The spleen identifies and destroys abnormal elliptical red blood cells. Surgically removing the spleen allows these cells to circulate much longer, which can significantly improve severe anemia and reduce or eliminate the need for regular blood transfusions.
Will removing my spleen cure Hereditary Elliptocytosis?
No, a splenectomy does not cure the genetic defect causing HE. Your red blood cells will remain elliptical, but because the spleen is no longer there to destroy them, they will survive longer in your bloodstream.
Why do HE patients often need their gallbladder removed?
Patients with HE process high levels of bilirubin from broken-down red blood cells, putting them at high risk for developing gallstones. If these gallstones cause severe pain or blockages, the gallbladder may need to be surgically removed through a cholecystectomy.

Questions for Your Doctor

  • • Is my (or my child’s) anemia 'compensated,' and does that mean we can stick to observation?
  • • Should we start a daily folic acid supplement to help with red blood cell production?
  • • At what point would we consider a splenectomy, and what are the specific risks and benefits for our case?
  • • If we go through with a splenectomy, what vaccinations and long-term precautions are necessary to prevent infections?
  • • Are there any clinical trials for new oral treatments like Mitapivat that I might be eligible for?

Questions for You

  • • How often am I feeling fatigued or noticing yellowing in my eyes (jaundice)?
  • • Am I able to keep up with my daily activities, or is anemia slowing me down?
  • • Am I prepared for the long-term commitment of monitoring and potential surgery if the condition is severe?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Clinical and molecular genetic analysis of a Chinese family with hereditary elliptocytosis caused by a novel mutation in the EPB41 gene.

    Cao M, Huang Z, Zhou H, et al.

    Journal of clinical laboratory analysis 2021; (35(6)):e23781 doi:10.1002/jcla.23781.

    PMID: 33942936
  2. 2

    Unravelling the genetic and phenotypic heterogeneity of SPTA1 gene variants in Hereditary Elliptocytosis and Hereditary Pyropoikilocytosis patients using next-generation sequencing.

    Anil More T, Kedar P

    Gene 2022; (843()):146796 doi:10.1016/j.gene.2022.146796.

    PMID: 35961434
  3. 3

    A large family of hereditary spherocytosis and a rare case of hereditary elliptocytosis with a novel SPTA1 mutation underdiagnosed in Taiwan: A case report and literature review.

    Shih YH, Huang YC, Lin CY, et al.

    Medicine 2023; (102(4)):e32708 doi:10.1097/MD.0000000000032708.

    PMID: 36705355
  4. 4

    Homozygous α-Spectrin (SPTA1) Variant Causing Persistent Hereditary Pyropoikilocytosis in a Newborn: A Case Report and Literature Review.

    Sayed J, Alabdulhadi AS, Alzahrani WA, et al.

    International medical case reports journal 2025; (18()):1303-1309 doi:10.2147/IMCRJ.S483359.

    PMID: 41098499
  5. 5

    Hereditary Pyropoikilocytosis as a Modifier of Sickle Cell Disease Severity.

    Lantz M, Dolatshahi L

    Journal of pediatric hematology/oncology 2025; (47(3)):128-130 doi:10.1097/MPH.0000000000003012.

    PMID: 40036694
  6. 6

    A SEVEN-YEAR-OLD MALE WITH CIRCULATING RED BLOOD CELLS SHOWING A THERMAL INJURY-LIKE MORPHOLOGY.

    Shackelford R, Ansari J, Veillon D, et al.

    The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society 2016; (168(1)):6-7.

    PMID: 26986859
  7. 7

    Inherited hemolytic anemia: a possessive beginner's guide.

    Mohandas N

    Hematology. American Society of Hematology. Education Program 2018; (2018(1)):377-381 doi:10.1182/asheducation-2018.1.377.

    PMID: 30504335
  8. 8

    A novel mutation in SPTA1 identified by whole exome sequencing in a Chinese family for hereditary elliptocytosis presenting with hyperbilirubinemia: A case report.

    Xi Y, Wang L, Zhang P, et al.

    Medicine 2019; (98(22)):e15800 doi:10.1097/MD.0000000000015800.

    PMID: 31145309
  9. 9

    Red cell membrane disorders.

    Narla J, Mohandas N

    International journal of laboratory hematology 2017; (39 Suppl 1()):47-52 doi:10.1111/ijlh.12657.

    PMID: 28447420
  10. 10

    Mechanics of diseased red blood cells in human spleen and consequences for hereditary blood disorders.

    Li H, Lu L, Li X, et al.

    Proceedings of the National Academy of Sciences of the United States of America 2018; (115(38)):9574-9579 doi:10.1073/pnas.1806501115.

    PMID: 30190436
  11. 11

    Exome sequencing results in successful diagnosis and treatment of a severe congenital anemia.

    Lacy JN, Ulirsch JC, Grace RF, et al.

    Cold Spring Harbor molecular case studies 2016; (2(4)):a000885 doi:10.1101/mcs.a000885.

    PMID: 27551681
  12. 12

    Prevention and treatment of infection in patients with an absent or hypofunctional spleen: A British Society for Haematology guideline.

    Ladhani SN, Fernandes S, Garg M, et al.

    British journal of haematology 2024; (204(5)):1672-1686 doi:10.1111/bjh.19361.

    PMID: 38600782
  13. 13

    Role of Partial Splenectomy in Hematologic Childhood Disorders.

    Attina' G, Triarico S, Romano A, et al.

    Pathogens (Basel, Switzerland) 2021; (10(11)) doi:10.3390/pathogens10111436.

    PMID: 34832592
  14. 14

    Designing a single-arm phase 2 clinical trial of mitapivat for adult patients with erythrocyte membranopathies (SATISFY): a framework for interventional trials in rare anaemias - pilot study protocol.

    Glenthøj A, van Beers EJ, van Wijk R, et al.

    BMJ open 2024; (14(7)):e083691 doi:10.1136/bmjopen-2023-083691.

    PMID: 39079928
  15. 15

    Mitapivat reprograms the RBC metabolome and improves anemia in a mouse model of hereditary spherocytosis.

    Matte A, Wilson AB, Gevi F, et al.

    JCI insight 2023; (8(20)).

    PMID: 37676741
  16. 16

    Mitapivat: A Review in Pyruvate Kinase Deficiency in Adults.

    Zhuang-Yan A, Shirley M

    Drugs 2023; (83(17)):1613-1620 doi:10.1007/s40265-023-01961-x.

    PMID: 37991635

This page provides information on treatment options for Hereditary Elliptocytosis for educational purposes only. Always consult your hematologist to determine the safest and most effective care plan for your or your child's specific case.

Stay up to date

Get notified when new research about Hereditary elliptocytosis is published.

No spam. Unsubscribe anytime.